France-based Juvisé Pharmaceuticals has acquired global marketing rights, excluding the US and Canada, for Johnson & Johnson (J&J)’s multiple sclerosis (MS) therapy Ponvory (ponesimod).
Juvisé Acquires Multiple Sclerosis Drug PONVORY and also Opens Its Capital
A €400 million financing was raised with Société Générale, Juvisé Pharmaceuticals historic and lead bank, supporting the funding of this latest acquisition together with the refinancing of its existing debt. Lazard and Latham & Watkins served as financial and legal advisors for Juvisé Pharmaceuticals, whereas White & Case served as legal advisors for Société Générale.
Congratulations to our Life Sciences and Healthcare team who were recently presented with seven accolades at the LMG Life Sciences Europe Awards 2021, announced 13th May.
This first transaction of Juvisé Pharmaceuticals with AstraZeneca is a logical next step after multiple worldwide deals accomplished by the French company with several other big pharmaceuticalncompanies over the past years.
Juvisé Pharmaceuticals: An atypical player in the world of pharmacy
On the back of a strong support from both relationship lenders and institutional investors,nsyndication was wrapped following a successful and oversubscribed early-bird phase. The covenantednfinancing is comprised of a EUR 128 million TLB alongside a EUR 85 million TLA. This syndication wasnmade possible through the collaboration with Juvisé Pharmaceuticals financial partners, with whomnthe company relies on long-term partnership characterized by openness and trust.